MRMD (MariMed) Research & Development: $0.0 Mil (TTM As of Mar. 2026)


What is MariMed Research & Development?

MariMed MRMD +4.75% Research & Development is $0.0 Mil as of Mar. 2026. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. MariMed's Research & Development for the three months ended in Mar. 2026 was $0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0.0 Mil.

MariMed  (OTCPK:MRMD) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

MariMed Research & Development Related Terms

MariMed Research & Development Historical Data

* Premium members only.

The historical data trend for MariMed's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MariMed Research & Development Chart

MariMed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MariMed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MariMed Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.0 Mil mean?
MariMed (MRMD) has a Research & Development of $0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on MariMed and its competitors.
Is MariMed's Research & Development too high?
MariMed's current Research & Development is $0.0 Mil.
How does MariMed's Research & Development compare to CPHI and RMTI?
MariMed's Research & Development of $0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on MariMed and its competitors. MariMed's current Research & Development is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MariMed stock overvalued right now?
Based on GuruFocus' analysis, MariMed (MRMD) is currently considered Possible Value Trap. The stock's GF Value™ is $0.16, compared to a current price of $0.07 — trading 54.5% below its estimated fair value. The current Research & Development is $0.0 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For MariMed (MRMD), the current Research & Development is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MariMed Business Description

Other Exchanges MRMD:Canada
Address 10 Oceana Way, Floor 2, Norwood, MA, USA, 02062
MariMed Inc is a multi-state cannabis operator in the United States dedicated to improving lives every day through its high-quality products. The company develops, owns, and manages seed to sale state-licensed, regulatory-compliant facilities for the cultivation, production, and dispensing of medicinal and adult-use cannabis. It has created and continues to develop its own brands of cannabis flower, concentrates, edibles, and other precision-dosed products utilizing its proprietary strains and formulations. The company also licenses its proprietary brands, along with other top cannabis products, in select domestic markets. Its operations are conducted in compliance with applicable state and local laws and regulations in the jurisdictions in which it operates.